Celldex Therapeutics
CLDX
27.42
-0.54
-1.93%
Celldex Therapeutics
US · CLDX
#2630 by market cap
Listed 1970
27.42
-0.54
-1.93%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Morgan Stanley Initiates Celldex Therapeutics(CLDX.US) With Buy Rating, Announces Target Price $61Market Newswire · 2026/11/10
-
Company notice
Celldex Therapeutics | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuersSEC · 2026/11/6
-
Morgan Stanley Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Raises Target Price to $61Market Newswire · 2026/11/9
-
Rating change
Analysts Offer Insights on Healthcare Companies: Celldex (CLDX), Summit Therapeutics (SMMT) and AbbVie (ABBV)TipRanks · 2026/10/14
-
Rating change
HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $64 Price TargetBenzinga · 2026/10/2
-
Rating change
LifeSci Capital Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Raises Target Price to $64Market Newswire · 2026/9/28
-
A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $29 to $68Market Newswire · 2026/11/7
-
Celldex Therapeutics Price Target Raised to $68.00/Share From $60.00 by Canaccord GenuityDow Jones · 2026/11/10
-
Rating change
H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $64Market Newswire · 2026/10/5
-
Company notice
Celldex Therapeutics | 8-K: Current reportSEC · 2026/9/22
-
Rating change
LifeSci Capital Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $64Market Newswire · 2026/10/3
-
Company notice
Celldex Therapeutics | SCHEDULE 13G/A: OthersSEC · 2026/10/7
-
Rating change
Barclays Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $53Market Newswire · 2026/11/6
-
CCORF Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Raises Target Price to $68Market Newswire · 2026/11/9
-
Company notice
Celldex Therapeutics | 8-K: Celldex Reports Third Quarter Financial Results and Provides Corporate UpdateSEC · 2026/11/6
-
Rating change
Cantor Fitzgerald Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Raises Target Price to $72Market Newswire · 2026/10/14
-
Rating change
Wells Fargo Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $72Market Newswire · 2026/10/15
-
Rating change
A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $50 to $88Market Newswire · 2026/9/24
-
Company notice
Celldex Therapeutics | 10-Q: Quarterly reportSEC · 2026/11/6
-
Rating change
Morgan Stanley Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $57Market Newswire · 2026/10/20
-
Rating change
Leerink Partners Maintains Outperform on Celldex Therapeutics, Raises Price Target to $88Benzinga · 2026/9/23
-
Rating change
Celldex Therapeutics Is Maintained at Overweight by Morgan StanleyDow Jones · 2026/9/23
-
Company notice
Celldex Therapeutics | SCHEDULE 13G/A: OthersSEC · 2026/8/15
-
Rating change
A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $50 to $100Market Newswire · 2026/9/23
-
Rating change
Celldex Therapeutics Is Maintained at Outperform by Leerink PartnersDow Jones · 2026/9/23
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Celldex Therapeutics discussion 0 comments